|
|
| Year : 2010 | Volume
: 21
| Issue : 2 | Page : 358 |
|
| Author's reply |
|
|
Mohammed Al-Jamal
Al-Barha St., Irbid, Jordan
Click here for correspondence address and email
| Date of Web Publication | 9-Mar-2010 |
|
|
 |
|
How to cite this article:
Al-Jamal M. Author's reply. Saudi J Kidney Dis Transpl 2010;21:358 |
To the Editor,
We thank for the interest and comments by Prof. S-M Alavian regarding our article about the prevalence of Hepatitis C Virus in hemodialysis patients. [1]
Regarding the use of erythropoietin, we agree that its use has significantly decreased the posttransfusion complications including HCV infection and we agree that this was not mentioned in our study, however, regarding the adherence to universal precautions, we have mentioned in brief that all units included in the study were required to strictly and equivocally adherent to these precautions.
Regarding the duration on hemodialysis, as shown in Table 4, the prevalence of HCV in patients dialyzed for more than 2 years was 46% as compared to only 11% in those dialyzed for less than 2 years (P value < 0.05), predicting the role of duration as a factor in acquiring HCV infection in HD, but we agree that this issue needs further evaluation and dividing the patients into other subgroups to prove the role of duration on HD as an independent risk factor is also important.
Regarding number of dialysis sessions and HBsAg status, we believe that these are important data which is better to be mentioned and we will take it into consideration in our future studies.
We would like to thank again for the interest in our article and look forward in identifying the risk factors and decreasing the seroconversion of our hemodialysis patients.
 References | |  |
| 1. | Al-Jamal M, Al-Qudah A, Al-Shishi KF, AlSarayreh A, Al-Quraan L. Hepatitis C virus (HCV) infection in hemodialysis patients in the south of Jordan. Saudi J Kidney Dis Transpl 2009;20(3):488-92.  |
Correspondence Address:
Mohammed Al-Jamal
Al-Barha St., Irbid
Jordan
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
|
|
|
|
|
|
|
